Male androgenetic alopecia (Part II)

Nyholt, 2003, Genetic basis of male pattern baldness, J Invest Dermatol, 121, 1561, 10.1111/j.1523-1747.2003.12615.x Devine, 1977, Minoxidil for severe hypertension after failure of other hypotensive drugs, Br Med J, 2, 667, 10.1136/bmj.2.6088.667 Prive, 1999, Drug Therapy: Treatment of Hair Loss, NEJM, 341, 964, 10.1056/NEJM199909233411307 Headington, 1984, Clinical and histologic studies of male pattern baldness treated with topical minoxidil, Curr Ther Res, 36, 1098 Li, 2001, Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: Possilbe involvement of sulfonylurea receptor 2B as a target of minoxidil, J Invest Dermatol, 117, 1594, 10.1046/j.0022-202x.2001.01570.x Kats, 1987, Long-term efficacy of topical minoxidil in male pattern baldness, J Am Acad Dermatol, 16, 648 Rietschel, 1987, Safety and efficacy of topical minoxidil in the management of androgenetic alopecia, J Am Acad Dermatol, 16, 677, 10.1016/S0190-9622(87)70087-5 Olsen, 1990, Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil, J Am Acad Dermatol, 22, 643, 10.1016/0190-9622(90)70089-Z Price, 1999, Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment, J Am Acad Dermatol, 41, 717, 10.1016/S0190-9622(99)70006-X Shapiro, 1998, Hair regrowth: Therapeutic agents, Dermatol Ther, 16, 341 Wilson, 1991, Contact dermatitis in reaction to 2% topical minoxidil solution, J Am Acad Dermatol, 24, 643, 10.1016/S0190-9622(08)80171-5 Van Neste, 2000, Finasteride increases anagen hair in men with androgenetic alopecia, Br J Dermatol, 143, 804, 10.1046/j.1365-2133.2000.03780.x Whiting, 1999, Measuring reversal of hair miniaturisation in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and post menopausal women, J Invest Dermatol, 4, 282, 10.1038/sj.jidsp.5640230 Price, 2002, Changes in hair weisth and ahir count in men with androgenetic alopecia after treatment with finasteride 1 mg daily, J Am Acad Dermatol, 46, 517, 10.1067/mjd.2002.120537 Drake, 1999, The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia, J Am Acad Dermatol, 41, 550 Roberts, 1999, Clinical dose ranging studies with finasteride, a type 2 5α reductase inhibitor, in men with male pattern hair loss, J Am Acad Dematol, 41, 555 Kaufman, 1998, Finasteride in the treatment of men with androgenetic alopecia, J Am Acad Dermatol, 39, 578, 10.1016/S0190-9622(98)70007-6 Leyden, 1999, Finasteride in the treatment of men with frontal male pattern hair loss, J Am Acad Dermatol, 40, 930, 10.1016/S0190-9622(99)70081-2 The Finasteride Male Pattern Hair Loss Study G. Long-term (5year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002:12:38-49 (Kaufman K. Long term (5 year) multinational experience with finasteride in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002:12;38-49). Stough, 2002, Finasteride improves male pattern hair loss in a randomized study in identical twins, Eur J Dermatol, 12, 32 Thai, 2002, Finasteride for female androgenetic alopecia, Br J Dermatol., 147, 812, 10.1046/j.1365-2133.2002.49084.x Tosti, 2001, Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia, J Eur Acad Dermatol Venereol, 15, 418, 10.1046/j.1468-3083.2001.00315.x Matzkin, 1996, Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia, Br J Urol, 78, 405, 10.1046/j.1464-410X.1996.00143.x Keetch, 1997, Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin or watchful waiting, Urology, 50, 901, 10.1016/S0090-4295(97)00453-6 Andriole, 1998, Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial, Urology, 52, 195, 10.1016/S0090-4295(98)00184-8 Physicians circular for Propecia. In. West Point: Merck; 1997. Sinclair, 2001, Androgenetic alopecia in men and women, Clin Dermatol, 19, 167, 10.1016/S0738-081X(00)00128-0 Trueb, 2001, Photographic documentation of the effectiveness of 1mg. Oral finasteride in treatment of androgenetic alopecia in the man in routine general practice in Switzerland, Schweiz Rundsch Med Prax, 29, 2087 Tollin, 1996, Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia – a Clinical Research Center study, J Clin Endocrinol Metab, 81, 1031, 10.1210/jc.81.3.1031 Matsumoto, 2002, The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trial, J Urol, 176, 2105 Wade, 2000, Reversible painful gynaecomastia induced by low dose finasteride (1 mg/day), Austral J Dermatol, 41, 5 Ferrando, 2002, Unilateral gynaecomastia induced by treatment with 1 mg of oral finasteride, Arch Dermatol, 138, 543, 10.1001/archderm.138.4.543 Chong, 2004, Viewpoints in Dermatology: Second Cite. A review of recent journal highlights, Clin Exp Dermatol, 29, 107, 10.1111/j.1365-2230.2004.01429.x Sovak, 2002, Fluridi, a rationally designed topical agent for androgenetic alopecia: First clinical experience, Dermatol Surg, 28, 678, 10.1046/j.1524-4725.2002.02017.x Sawaya, 1998, Novel agents for the treatment of androgenetic alopecia, Semin Cutan Med Surg, 17, 276, 10.1016/S1085-5629(98)80024-2 Dutasteride (Avodart) for Benign Prostatic Hyperplasia. Med Lett Drugs Ther 2002; 44:109–110. Shiell, 2001, Modern hair restoration surgery, Clin Dermatol, 19, 179, 10.1016/S0738-081X(00)00129-2